Michael I. Miller

发表

Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults

J. Kahn, P. Barditch-Crovo, A. Collier, 2001, Antimicrobial Agents and Chemotherapy.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection

M. Wulfsohn, K. Squires, A. Pozniak, 2003, Annals of Internal Medicine.

Differentiation into an Effector Memory Phenotype Potentiates HIV-1 Latency Reversal in CD4+ T Cells

D. Hazuda, R. Sékaly, S. Deeks, 2019, Journal of Virology.

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients: Final 5-Year Results From STARTMRK

Y. Yazdanpanah, M. Saag, J. Rockstroh, 2013, Journal of acquired immune deficiency syndromes.

Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs

D. Richman, J. Martinez-Picado, C. Katlama, 2013, The Lancet.

In Vitro Susceptibility of Adefovir-Associated Hepatitis B Virus Polymerase Mutations to other Antiviral Agents

Huiling Yang, W. Delaney, Michael I. Miller, 2006, Antiviral therapy.

Cross-Resistance Testing of Next-Generation Nucleoside and Nucleotide Analogues against Lamivudine-Resistant HBV

Huiling Yang, W. Delaney, Michael I. Miller, 2005, Antiviral therapy.

Resistance to Chronic Wasting Disease in Transgenic Mice Expressing a Naturally Occurring Allelic Variant of Deer Prion Protein

B. Chesebro, C. Favara, E. Williams, 2007, Journal of Virology.

Differentiation to an effector memory phenotype potentiates HIV-l latency reversal in CD4+ T cells

D. Hazuda, R. Sékaly, S. Deeks, 2019 .

Barriers to a Cure: New concepts in targeting and eradicating HIV-1 reservoirs

Jeffrey, D. Richman, J. Martinez-Picado, 2013 .

Efficacy of Raltegravir Versus Efavirenz When Combined With Tenofovir/ Emtricitabine in Treatment-Naïve HIV-1–Infected Patients: Week-192 Overall and Subgroup Analyses From STARTMRK

A. Lazzarin, M. Saag, J. Rockstroh, 2012, HIV Clinical Trials.

Viability of primary osteoblasts after treatment with tenofovir alafenamide: Lack of cytotoxicity at clinically relevant drug concentrations

K. Kitrinos, A. Ray, D. Babusis, 2017, PloS one.

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

Christos J. Petropoulos, Wei Huang, D. Hazuda, 2009, Journal of Virology.

Comparative Selection of the K65R and M184V/I Mutations in Human Immunodeficiency Virus Type 1-Infected Patients Enrolled in a Trial of First-Line Triple-Nucleoside Analog Therapy (Tonus IMEA 021)

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2005, Journal of Virology.

Antiretroviral Agents Restore Mycobacterium-Specific T-Cell Immune Responses and Facilitate Controlling a Fatal Tuberculosis-Like Disease in Macaques Coinfected with Simian Immunodeficiency Virus andMycobacterium bovis BCG

M. Simon, N. Letvin, P. Sehgal, 2001, Journal of Virology.

Drug resistance assessment following administration of RSV fusion inhibitor presatovir to participants experimentally infected with respiratory syncytial virus.

S. Lewis, R. Jordan, T. Cihlar, 2020, The Journal of infectious diseases.

Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial.

M. Wulfsohn, J. Kahn, S. Lagakos, 1999, JAMA.

Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates.

H. Mo, Huiling Yang, W. Delaney, 2009, Antiviral research.

Genotypic Determinants of the Virological Response to Tenofovir Disoproxil Fumarate in Nucleoside Reverse Transcriptase Inhibitor-Experienced Patients

F. Brun-Vézinet, B. Masquelier, D. Costagliola, 2003, Antiviral therapy.

Pharmacist-Driven Implementation of Fast Identification and Antimicrobial Susceptibility Testing Improves Outcomes for Patients with Gram-Negative Bacteremia and Candidemia

S. Baker, Sahil Sheth, Michael I. Miller, 2020, Antimicrobial Agents and Chemotherapy.

Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic Pathways

D. Hazuda, C. Petropoulos, R. Danovich, 2009, Journal of Virology.